cmAngio® vs Viz HCM

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by CureMetrix
VS
by Viz.ai

AI Verdict

cmAngio® and Viz HCM both leverage AI in cardiology but serve distinct clinical purposes. cmAngio® focuses on detecting Breast Arterial Calcifications from mammograms to assess cardiovascular risk, primarily aiding radiologists and OB/GYNs. In contrast, Viz HCM analyzes ECGs for real-time detection of Hypertrophic Cardiomyopathy and streamlines care coordination for cardiologists and emergency medicine.

Choose cmAngio® if…

Choose cmAngio if your primary goal is to leverage existing mammography screenings for proactive cardiovascular risk assessment in women. This tool is ideal for integrating AI-powered detection of Breast Arterial Calcifications (BAC) into radiology workflows, providing valuable insights into cardiovascular health without additional radiation or procedures.

View cmAngio® →

Choose Viz HCM if…

Choose Viz HCM if your priority is real-time detection and rapid care coordination for suspected Hypertrophic Cardiomyopathy (HCM) patients. This solution excels at analyzing ECGs to quickly identify potential HCM cases and streamline the referral process to appropriate cardiac specialists, significantly reducing time to diagnosis and treatment.

View Viz HCM →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature cmAngio® Viz HCM
Pricing Paid, out-of-pocket Unknown
Deployment Cloud-based, integrates with any DICOM-compliant viewer Unknown
BAA Available Unknown Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Viz HCM

While cmAngiou00ae emphasizes quick installation and DICOM compatibility, Viz HCM's focus on real-time mobile alerts and seamless integration with EHR/PACS suggests a more dynamic and integrated user experience. The ability to receive critical notifications and coordinate care on a mobile device offers a significant usability advantage for rapid clinical workflows.

Clinical Value

Viz HCM

Both tools are FDA-cleared and address important clinical needs. cmAngiou00ae provides valuable insights into cardiovascular risk from existing mammograms, but Viz HCM directly impacts the diagnosis and treatment time for Hypertrophic Cardiomyopathy, a potentially fatal condition, through real-time detection and care coordination. Viz HCM's emphasis on reducing diagnosis time and streamlining care for a critical cardiac condition offers a more immediate and direct clinical impact.

Pricing & Value

Viz HCM

Viz HCM offers greater transparency with its subscription-based pricing and explicitly highlights CMS reimbursement for specific CPT codes, providing a clear path for financial viability for healthcare providers. In contrast, cmAngiou00ae's pricing details are not publicly available, making it harder to assess its value proposition despite potential no-cost offers.

Enterprise Readiness

Viz HCM

Viz HCM explicitly states 'seamless integration with existing clinical workflows, EHR, and PACS systems' and confirms the availability of a Business Associate Agreement (BAA), which are crucial for enterprise adoption. While cmAngiou00ae is HIPAA-compliant and cybersecure, its BAA details require direct vendor contact, making Viz HCM's readiness more clearly articulated.

Innovation

Viz HCM

Both tools leverage AI for detection. cmAngiou00ae innovates by extracting new cardiovascular risk information from existing mammography data. However, Viz HCM's innovation extends beyond detection to include real-time, mobile-based alerts and automated care coordination, which represents a more comprehensive and transformative approach to managing a critical disease.

Support & Docs

Tie

Neither the provided structured facts nor a general web search yielded specific, publicly available details regarding comprehensive support services or extensive documentation for either cmAngiou00ae or Viz HCM. While both companies likely offer support to their customers, there is insufficient information to differentiate them on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature cmAngio® Viz HCM
Tool Name cmAngiou00ae Viz HCM
Company CureMetrix Viz.ai
Primary Function AI software for detecting Breast Arterial Calcifications (BAC) on mammograms AI tool that uses real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy (HCM)
Key Feature 1 AI-based detection of Breast Arterial Calcifications (BAC) AI-powered ECG analysis for Hypertrophic Cardiomyopathy (HCM) detection
Key Feature 2 Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams Real-time disease detection from electrocardiograms

Videos

Demos, reviews, and walkthroughs featuring cmAngio® and Viz HCM.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

cmAngiou00ae by CureMetrix is FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. Viz HCM by Viz.ai is an FDA-cleared AI tool that uses real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy (HCM).
cmAngiou00ae processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. Viz HCM analyzes real-time 12-lead electrocardiograms (ECGs).
cmAngiou00ae provides visualization of BAC location on a scorecard, enabling BAC identification and reporting without additional radiation or procedures. Viz HCM offers real-time disease detection from ECGs, mobile-based alerts and notifications to multidisciplinary care teams, and automated direction of patients to appropriate care specialists, aiming to reduce time to diagnosis and treatment for HCM.
For cmAngiou00ae, pricing details are not publicly available, and physicians need to contact the vendor for information. Viz HCM is subscription-based, with CMS reimbursement available for CPT codes 0764T and 0765T, with a national payment rate of $128.90 effective January 1, 2025.
cmAngiou00ae is categorized under Cardiology AI, OB/GYN AI, and Radiology & Imaging AI, and is relevant for Cardiology, Obstetrics & Gynecology, and Radiology specialties. Viz HCM is categorized under Cardiology AI and Clinical Decision Support & Reference, and is designed for Cardiology, Emergency Medicine, and Hospital Medicine specialties.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.